Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
Engel, J., Richters, A., Getlik, M., Tomassi, S., Keul, M., Termathe, M., Lategahn, J., Becker, C., Mayer-Wrangowski, S., Grutter, C., Uhlenbrock, N., Krull, J., Schaumann, N., Eppmann, S., Kibies, P., Hoffgaard, F., Heil, J., Menninger, S., Ortiz-Cuaran, S., Heuckmann, J.M., Tinnefeld, V., Zahedi, R.P., Sos, M.L., Schultz-Fademrecht, C., Thomas, R.K., Kast, S.M., Rauh, D.(2015) J Med Chem 58: 6844-6863
- PubMed: 26275028 
- DOI: https://doi.org/10.1021/acs.jmedchem.5b01082
- Primary Citation of Related Structures:  
5D10, 5D11, 5D12 - PubMed Abstract: 
Receptor tyrosine kinases represent one of the prime targets in cancer therapy, as the dysregulation of these elementary transducers of extracellular signals, like the epidermal growth factor receptor (EGFR), contributes to the onset of cancer, such as non-small cell lung cancer (NSCLC) ...